Redeye comments on Cantargia's third quarter report 2025. Cantargia is planning for a pivotal study in pancreatic cancer in 2026, pending the finalisation of the IL1RAp diagnostic and funding. We have therefore changed our valuation assumptions. A new bispecific antibody, CAN14, is being developed for immunological diseases. The next catalyst is the survival readout of TRIFOUR in TNBC scheduled for this year.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/